Clinical Trials Articles
According to randomized controlled trials, repeat intravenous immune globulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barré syndrome (GBS) nonresponders. Furthermore, the delineation between GBS and acute onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) can be particularly challenging and carries therapeutic implications.
In a Phase III, double-blind, three-way crossover trial, sebetralstat given on-demand for treatment of hereditary angioedema (HAE) attacks was shown to result in faster times to the start of symptom relief, reduction in attack severity and complete attack resolution than placebo treatment.
Imperial College Healthcare NHS Trust has enrolled the first United Kingdom (UK) patients who have received an experimental messenger RNA (mRNA) therapy — a type of immunotherapy treatment called mRNA-4359 — in its Phase I/II clinical trial.
A new study shows efgartigimod significantly increased sustained platelet count responses compared with placebo in patients with chronic immune thrombocytopenia, including those who had received multiple previous immune thrombocytopenia therapies.
A large clinical trial of Eli Lilly's experimental Alzheimer's medication, donanemab found the drug slowed declines in patients' ability to think clearly and perform daily tasks by more than a third.
The first clinical trial for Down syndrome regression disorder is being funded by a five-year $5.3 million grant.
A clinical trial of the Vaxina (the CF33-hNIS virus) designed to kill cancer cells has begun.
An investigational antisense oligo-nucleotide (donidalorsen) that acts by degrading plasma prekallikrein messenger RNA was evaluated in patients with hereditary angioedema (HAE) and C1 inhibitor deficiency to assess whether this agent can reduce the frequency of angioedema attacks and the burden of disease.
While intravenous immune globulin (IVIG) therapy is efficacious for patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the lack of biomarkers for disease activity makes the need for ongoing treatment difficult to assess.
Eltrombopay found to improve therapy for aplastic anemia.
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.